Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. Sep 29, 2017 09:00 JST
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop Jun 16, 2017 10:00 JST
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology Apr 04, 2017 14:50 JST
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma Mar 24, 2017 07:10 JST
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017 Mar 07, 2017 15:50 JST
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer Feb 07, 2017 17:00 JST
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia Oct 21, 2016 18:00 JST
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 Jul 03, 2015 19:00 JST Small but heading for the big time
